Enterovirus 71 (EV-71) is a common virus primarily responsible for hand, foot, and mouth disease and other severe neurological infections. Treatment is mainly symptom-oriented, aiming to alleviate symptoms, prevent complications, and promote recovery.
Since EV-71 is a viral infection, there are currently no specific antiviral drugs available. Therefore, the focus of treatment is on supportive care and symptom management.
EV-71 treatment is divided into supportive care and specific antiviral therapy. Supportive care mainly includes rest, hydration with electrolytes, pain relief, and fever reduction.
Specific antiviral treatments involve the use of antiviral-active drugs such as pleconaril, but these are not yet approved in all regions and have limited efficacy.
The main clinical manifestations of EV-71 infection include hand, foot, and mouth disease, pharyngitis, pneumonia, and neurological infections. Treatment is applicable to all patients infected with EV-71, especially those with severe symptoms or high-risk complications.
Supportive care methods include oral rehydration, intravenous electrolyte and nutrient infusion, and symptomatic relief, with specific dosages adjusted according to the patient's age, weight, and severity of illness.
If antiviral drugs are used, they should be administered under medical supervision, strictly following the instructions in the medication guide for dosage adjustments.
Supportive care can effectively relieve symptoms, prevent dehydration, and electrolyte imbalance-related complications.
Supportive care is generally safe, but attention should be paid to maintaining the balance of hydration and electrolytes to avoid excess or deficiency.
Patients with EV-71 infection should avoid using non-steroidal anti-inflammatory drugs to prevent worsening of the condition.
There are few interactions between EV-71 treatment drugs and other medications, but caution is advised regarding potential interactions with antiviral drugs.
Research indicates that early supportive care can effectively improve clinical symptoms and reduce the incidence of severe complications.
Currently, treatment for EV-71 mainly involves supportive care. Specific antiviral treatments are still under research. Patients should choose appropriate treatment options based on medical advice.
The duration of treatment for Enterovirus 71 varies depending on the severity of the infection and the overall health of the patient. Mild cases may only require a few days of rest and symptom management, while severe cases may need hospitalization for several weeks to control the illness and prevent complications.
What dietary precautions should patients observe during Enterovirus 71 infection?During Enterovirus 71 infection, patients should maintain a light diet, consuming foods rich in vitamins and proteins to boost immunity. Avoid spicy, greasy, and high-sugar foods to prevent symptom aggravation. Adequate hydration also helps facilitate recovery.
Are there any special medications required in the treatment of Enterovirus 71?The main treatment for Enterovirus 71 is symptomatic, and there are currently no specific antiviral drugs targeting this virus. Doctors may prescribe antipyretics or analgesics to relieve discomfort. Severe cases may require hospitalization for supportive care, such as intravenous fluids and respiratory support.
How can I effectively prevent reinfection after contracting Enterovirus 71?Preventing reinfection involves maintaining good hygiene practices, such as frequent handwashing, avoiding contact with contaminated objects and surfaces, and keeping the environment clean. Adequate rest and a balanced diet also help strengthen immunity, reducing the risk of reinfection.
What is the success rate of treatment for Enterovirus 71?The success rate of treatment for Enterovirus 71 is generally high, especially in mild cases. However, the prognosis for severe cases may be influenced by factors such as age, immune status, and timely treatment. Prompt medical attention and consistent adherence to the treatment plan are key to improving outcomes.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
